|
1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sullivan PR: Brain tumors. N Engl J Med.
344:1478author reply 1479. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen J, McKay RM and Parada LF: Malignant
glioma: lessons from genomics, mouse models, and stem cells. Cell.
149:36–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lau A, Villeneuve NF, Sun Z, Wong PK and
Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res. 58:262–270.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dinkova-Kostova AT, Liby KT, Stephenson
KK, et al: Extremely potent triterpenoid inducers of the phase 2
response: correlations of protection against oxidant and
inflammatory stress. Proc Natl Acad Sci USA. 102:4584–4589. 2005.
View Article : Google Scholar
|
|
6
|
Kwak MK, Itoh K, Yamamoto M, Sutter TR and
Kensler TW: Role of transcription factor Nrf2 in the induction of
hepatic phase 2 and antioxidative enzymes in vivo by the cancer
chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med.
7:135–145. 2001.PubMed/NCBI
|
|
7
|
Shih AY, Li P and Murphy TH: A
small-molecule-inducible Nrf2-mediated antioxidant response
provides effective prophylaxis against cerebral ischemia in vivo. J
Neurosci. 25:10321–10335. 2005. View Article : Google Scholar
|
|
8
|
Yan W, Wang HD, Feng XM, Ding YS, Jin W
and Tang K: The expression of NF-E2-related factor 2 in the rat
brain after traumatic brain injury. J Trauma. 66:1431–1435. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Fields J, Zhao C, et al: Role of
Nrf2 in protection against intracerebral hemorrhage injury in mice.
Free Radic Biol Med. 43:408–414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayes JD and McMahon M: NRF2 and KEAP1
mutations: permanent activation of an adaptive response in cancer.
Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hayes JD and McMahon M: The double-edged
sword of Nrf2: subversion of redox homeostasis during the evolution
of cancer. Mol Cell. 21:732–734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kensler TW and Wakabayashi N: Nrf2: friend
or foe for chemoprevention? Carcinogenesis. 31:90–99. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Homma S, Ishii Y, Morishima Y, et al: Nrf2
enhances cell proliferation and resistance to anticancer drugs in
human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamadori T, Ishii Y, Homma S, et al:
Molecular mechanisms for the regulation of Nrf2-mediated cell
proliferation in non-small-cell lung cancers. Oncogene.
45:4768–4777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lister A, Nedjadi T, Kitteringham NR, et
al: Nrf2 is overexpressed in pancreatic cancer: implications for
cell proliferation and therapy. Mol Cancer. 10:372011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim TH, Hur EG, Kang SJ, et al: NRF2
blockade suppresses colon tumor angiogenesis by inhibiting
hypoxia-induced activation of HIF-1α. Cancer Res. 71:2260–2275.
2011.PubMed/NCBI
|
|
17
|
Pan H, Wang H, Zhu L, Mao L, Qiao L and Su
X: The role of Nrf2 in migration and invasion of human glioma cell
U251. World Neurosurg. Nov 7–2011.(Epub ahead of print).
|
|
18
|
Rousseau A, Mokhtari K and Duyckaerts C:
The 2007 WHO classification of tumors of the central nervous system
- what has changed? Curr Opin Neurol. 21:720–727. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bustin SA, Benes V, Garson JA, et al: The
MIQE guidelines: minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu Z, Lin D, Yuan J, et al: Overexpression
of osteopontin is associated with more aggressive phenotypes in
human non-small cell lung cancer. Clin Cancer Res. 11:4646–4652.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis--correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang M, Tang J, Liu S, Yoshida D and
Teramoto A: Expression of cathepsin B and microvascular density
increases with higher grade of astrocytomas. J Neurooncol. 71:3–7.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM
and Gelmon KA: Ki67 in breast cancer: prognostic and predictive
potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moi P, Chan K, Asunis I, Cao A and Kan YW:
Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic
leucine zipper transcriptional activator that binds to the tandem
NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl
Acad Sci USA. 91:9926–9930. 1994. View Article : Google Scholar
|
|
25
|
Padmanabhan B, Tong KI, Ohta T, et al:
Structural basis for defects of Keap1 activity provoked by its
point mutations in lung cancer. Mol Cell. 21:689–700. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singh A, Misra V, Thimmulappa RK, et al:
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
PLoS Med. 3:e4202006. View Article : Google Scholar
|
|
27
|
Shibata T, Kokubu A, Gotoh M, et al:
Genetic alteration of Keap1 confers constitutive Nrf2 activation
and resistance to chemotherapy in gallbladder cancer.
Gastroenterology. 135:1358–1368. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nioi P and Nguyen T: A mutation of Keap1
found in breast cancer impairs its ability to repress Nrf2
activity. Biochem Biophys Res Commun. 362:816–821. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shibata T, Ohta T, Tong KI, et al: Cancer
related mutations in NRF2 impair its recognition by Keap1-Cul3 E3
ligase and promote malignancy. Proc Natl Acad Sci USA.
105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Konstantinopoulos PA, Spentzos D,
Fountzilas E, et al: Keap1 mutations and nrf2 pathway activation in
epithelial ovarian cancer. Cancer Res. 71:5081–5089. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Merikallio H, Paakko P, Kinnula VL, Harju
T and Soini Y: Nuclear factor erythroid-derived 2-like 2 (Nrf2) and
DJ1 are prognostic factors in lung cancer. Hum Pathol. 43:577–584.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
et al: RNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wiesner FG, Magener A, Fasching PA, et al:
Ki-67 as a prognostic molecular marker in routine clinical use in
breast cancer patients. Breast. 18:135–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thompson CB: Apoptosis in the pathogenesis
and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Niture SK and Jaiswal AK: Nrf2
up-regulates anti-apoptotic protein Bcl-2 and prevents cellular
apoptosis. J Biol Chem. 287:9873–9886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Choi YK, Kim CK, Lee H, et al: Carbon
monoxide promotes VEGF expression by increasing HIF-1α protein
level via two distinct mechanisms, translational activation and
stabilization of HIF-1α protein. J Biol Chem. 285:32116–32125.
2010.PubMed/NCBI
|
